IQVIA Holdings Inc. (IQV)
| Market Cap | 28.31B -22.7% |
| Revenue (ttm) | 16.31B +5.9% |
| Net Income | 1.36B -0.9% |
| EPS | 7.84 +4.7% |
| Shares Out | 169.60M |
| PE Ratio | 21.29 |
| Forward PE | 13.15 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,265,518 |
| Open | 169.98 |
| Previous Close | 168.85 |
| Day's Range | 165.60 - 172.52 |
| 52-Week Range | 134.65 - 247.05 |
| Beta | 1.36 |
| Analysts | Buy |
| Price Target | 236.33 (+41.57%) |
| Earnings Date | Feb 5, 2026 |
About IQV
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to ... [Read more]
Financial Performance
In 2025, IQVIA Holdings's revenue was $16.31 billion, an increase of 5.87% compared to the previous year's $15.41 billion. Earnings were $1.36 billion, a decrease of -0.95%.
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for IQV stock is "Buy." The 12-month stock price target is $236.33, which is an increase of 41.57% from the latest price.
News
Oakmark Global All Cap Strategy Q4 2025 Performance Review
Oakmark Global All Cap Strategy portfolio's return was 4.99% (net) for the reporting period vs. MSCI World Index that returned 3.12% for the same period. Contributors in the quarter were DSV, IQVIA Ho...
IQVIA and Duke Clinical Research Institute Announce Strategic Collaboration to Advance Clinical Research in Obesity and Related Conditions
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healt...
IQVIA Holdings Inc. (IQV) Q4 2025 Earnings Call Transcript
IQVIA Holdings Inc. (IQV) Q4 2025 Earnings Call Transcript
IQVIA forecasts weak annual profit on higher interest expenses
Healthcare data and clinical research provider IQVIA Holdings on Thursday forecast annual profit below Wall Street expectations, weighed down by higher interest costs, even as strong fourth-quarter re...
IQVIA Reports Fourth-Quarter and Full-Year 2025 Results; Issues Full-Year 2026 Guidance
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the...
IQVIA and Boehringer Ingelheim announce strategic long-term global commercial data foundation transformation collaboration
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healt...
IQVIA Named to the Fortune® World's Most Admired Companies™ List, Ranked No. 1 in Its Sector for Fifth Consecutive Year
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, was named No. 1 in its catego...
IQVIA to Announce Fourth-Quarter and Full-Year 2025 Results on February 5, 2026
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the...
IQVIA: Increasingly Indispensable In Drug Development
IQVIA Holdings is positioned as the indispensable data and technology backbone of the life sciences industry, far beyond a traditional CRO. Long-term revenue visibility is underpinned by a record $32....
IQVIA Announces Strategic Collaboration with AWS, Naming AWS as Preferred Agentic Cloud Provider to Power Next-Generation AI Platform
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE: IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and heal...
Oakmark Global Concentrated Strategy Q3 2025 Top Contributors And Detractors
Alibaba Group was a contributor during the quarter. The stock price rose significantly following earnings that reflected rapid Chinese AI growth. Alphabet was a contributor during the quarter. The sto...
IQVIA Holdings Inc. (IQV) Presents at UBS Global Healthcare Conference 2025 Transcript
IQVIA Holdings Inc. ( IQV) UBS Global Healthcare Conference 2025 November 11, 2025 12:30 PM EST Company Participants Ari Bousbib - CEO & Chairman Conference Call Participants Daniel Leonard - UBS Inv...
Oakmark Concentrated Strategy: 6 Stocks That Raised Guidance And Drove Innovation
Warner Bros Discovery reported merger with Paramount-Skydance could generate meaningful cost synergies and create a scaled competitor with a deep and unmatched content library. Innovations in the Goog...
Dr. William G. Kaelin Jr. joins IQVIA Board of Directors
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, announced the appointment of ...
IQVIA Holdings Inc. (IQV) Q3 2025 Earnings Call Transcript
IQVIA Holdings Inc. (NYSE:IQV) Q3 2025 Earnings Call October 28, 2025 9:00 AM EDT Company Participants Kerri Joseph - SVP of Investment Relation & Treasury Ari Bousbib - CEO & Chairman Ronald Bruehlm...
IQVIA narrows annual profit forecast amid continued research contract cancellations
IQVIA Holdings on Tuesday narrowed its annual profit forecast, trimming the upper end of its outlook, as it expects cancellations of research contracts from pharmaceutical clients to persist into the ...
IQVIA Reports Third-Quarter 2025 Results
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the...
Smart Acquisitions And Profit Margin Growth Amid Strategic Repositioning
We purchased several new fund holdings across various sectors. Sempra has been shifting its strategic focus from its highly regulated California operations to its growing presence in Texas. Regeneron ...
IQVIA CEO Ari Bousbib to Speak at UBS Global Healthcare Conference on November 11, 2025
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the...
IQVIA to Announce Third-Quarter 2025 Results on October 28, 2025
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the...
ILMN Stock vs. IQV Stock
Amid increased competition from China's MGI Tech, Illumina's stock (NASDAQ: ILMN) has dropped by 11% in a week. MGI Tech's DNA sequencers are reportedly gaining market share, and despite a recent decl...
IQVIA Receives WCG Pinnacle Award for Excellence in Site Relationships
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healt...
IQVIA: A Positive Long-Term Outlook Despite Trump Legislation
Companies and institutions continue to conduct clinical trials, indicating that the CRO market demand will continue to grow. The revenues of the TAS segment increased by 7.67% in the first half of 202...
IQVIA Announces Launch of Clinical Trial Financial Suite, a Next-Generation Platform for Integrated Financial Management
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healt...
IQVIA names Michael Fedock as financial chief
IQVIA Holdings on Tuesday named insider Michael Fedock as Chief Financial Officer, effective February 28, 2026, succeeding Ron Bruehlman who is set to retire.